Several of these inhibitors target BTK, such as ibrutinib or acalabrutinib, which are currently used or have been proposed for the treatment of CLL, MCL, WM, and DLBCL [86,87,88,89,90]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.